N/A N=40 Effect of Structural Remodeling on Scar Formation as Assessed by DE-MRI of the Left Atrium
Atrial Fibrillation
Primary: Left Atrial (LA) Remodeling Pre-ablation — 2; 31; 7; 0 participants — p=0.48
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=40 Ablation Targets of Scar-related Ventricular Tachycardia Identified by Dynamic Functional Substrate Mapping
Tachycardia, Ventricular
Primary: Number of Participants With Recurrence of Ventricular Tachycardia — 13; 13 Participants
N/A N=80 Supraventricular Tachycardia Collection Study
Supraventricular Arrhythmias
Primary: Number of Electrocardiograms (ECGs) Collected — 77; 67; 53 ECG
N/A N=1 Stereotactic Ablative Radiotherapy for Refractory Ventricular Tachycardia
Refractory Ventricular Tachycardia
Primary: ICD (Implantable Cardioverter Defibrillator) Shock Free Survival — 1 Participants
N/A N=31 Characterising the Stable and Dynamic Left Atrial Substrate in Atrial Fibrillation
Atrial Fibrillation
Primary: To Define the Normal Range of Voltage Amplitude — 2.00; 1.92 mV
N/A N=152 Substrate Ablation Guided by High Density Mapping in Atrial Fibrillation
Atrial Fibrillation
Primary: Percentage of Patient With Atrial Fibrillation Termination at the End of the Procedure — 95; 60 Percentage of participants
N/A N=18 Multimodality Assessment of Ventricular Scar Arrhythmogenicity.
Ventricular Tachycardia
Primary: Electrogram Duration at Digital Twin Predicted Sites Compared to Non-predicted Sites — 77.5; 65.7 ms
N/A N=35 Prospective Elimination Of Distal Coronary Sinus-Left Atrial Connections for Atrial Fibrillation Ablation Trial
Atrial Fibrillation · Arrhythmias, Cardiac
Primary: Recurrence Rate of Atrial Arrhythmias — 8; 14; 7; 1 participants — p=0.047
N/A N=24 Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study
Persistent Atrial Fibrillation · Longstanding Persistent Atrial Fibrillation
Primary: Primary Safety Endpoint — 0; 0; 4.2; 0 percentage of participants
N/A N=20 Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation
Ventricular Tachycardia
Primary: Number of Participants With Procedural Success — 8; 6 Participants
N/A N=81 Tragus Stimulation to Prevent Atrial Fibrillation After Cardiac Surgery
Atrial Fibrillation
Primary: Time to the First Episode of Atrial Fibrillation (AF) >30 Seconds — 53.1; 52.2 hours — p=0.60
Phase 3 N=55 AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation
Atrial Fibrillation
Primary: Percent of Patients Free From AF and Off Class I and III Anti-arrhythmic Drugs as Determined by Holter Monitoring at 6 Months. — 74 percentage of subjects
N/A N=83 Effectiveness of Ripple Mapping in Atrial Tachycardia Ablation
Atrial Tachycardia
Primary: A Composite of the Total Number of Participants With Either Tachycardia Change or Tachycardia Termination With First Ablation Set. — 38; 29 Participants
N/A N=26 Dual Epicardial Endocardial Persistent Atrial Fibrillation(AF) Study (Staged DEEP)
Atrial Fibrillation
Primary: Number of Patients With Pre-specified Safety Endpoints Occurring in the First 30 Days Post-index Procedure or Hospital Discharge, Whichever is Longer. — 3 Participants
N/A N=24 Contrast ICE for Myocardial Scar in VT Ablations
Ventricular Tachycardia · Ischemic Cardiomyopathy
Primary: Number of Subjects With Myocardial Scar on Echo and Voltage Maps — 20 Participants
Phase 3 N=210 Tailored Treatment of Permanent Atrial Fibrillation
Atrial Fibrillation
Primary: Chronic Effectiveness — 56; 26 percentage of participants with success — p=<0.0001
N/A N=365 ABLATE Post Approval Study - Synergy Ablation Lesions for Non-Paroxysmal Atrial Fibrillation
Persistent Atrial Fibrillation · Longstanding Persistent Atrial Fibrillation
Primary: The Number of Participants Free From Atrial Fibrillation (AF), Atrial Flutter or Atrial Tachycardia While Off Class I and Class III Antiarrhythmic Drugs for at Least 4…
Phase 3 N=75 Concomitant Utilization of Radio Frequency Energy for Atrial Fibrillation (CURE-AF) Study
Atrial Fibrillation
Primary: Efficacy Endpoint: The Percent of Patients Off Class I and/or III Antiarrhythmic Drugs and Out of Atrial Fibrillation as Determined by 24 Hour Holter Recording Conducted…
N/A N=180 Pan-Asia United States PrEvention of Sudden Cardiac Death Catheter Ablation Trial
Ventricular Tachycardia (VT)
Primary: Freedom From Recurrent VT, Cardiovascular Rehospitalization, and All-cause Mortality — 33; 25; 28; 27 Participants
N/A N=374 Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation
Atrial Fibrillation
Primary: Number of Participants Free From Documented AF After One Ablation Procedure — 158; 124 Participants
N/A N=300 TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: Freedom From Recurrence of Symptomatic Atrial Fibrillation, Atrial Tachycardia or Atrial Flutter — 99; 93 participants
N/A N=20 Imaging With a Radio Tracer to Guide VT Ablations
Ventricular Tachycardia · Arrhythmia
Primary: Comparison of the Percentage of Patients With Scar in Each Segment as Determined by MIBG SPECT Versus Electroanatomic at Baseline — 2; 4; 1; 4 Participants
Phase 3 N=75 Medtronic Concomitant Utilization of Radio Frequency for Atrial Fibrillation CURE-AF/Persistent
Atrial Fibrillation
Primary: Efficacy Endpoint: The Percent of Patients Off Class I or III Antiarrhythmic Drugs and Out of AF as Determined by 24 Hour Holter Recording at 9 Months — 42.6 percentage…
N/A N=140 A New Operation for the Treatment for Long-standing Atrial Fibrillation
Cardiovascular Disease
Primary: Numbers of Participants Free From AF — 20; 96; 20; 97 Participants
N/A N=3,160 Exclusion of Intra-atrial Thrombus Before Catheter Ablation
Atrial Fibrillation · Thrombi
Primary: Number of Patients With Atrial Thrombus and a Zero ATE Score — 2; 816; 27; 2227 Participants
N/A N=439 Evaluation Of New Onset Postoperative Atrial Fibrillation
Atrial Fibrillation New Onset
Primary: Primary Safety Endpoint — 3.9; 3.6 percentage of participants
N/A N=107 The Dynamics of Human Atrial Fibrillation
Atrial Fibrillation · Atrial Tachyarrhythmia
Primary: Survival Free of Atrial Fibrillation — 28; 31 participants
Phase 3 N=165 SMART-SF Radiofrequency Ablation Safety Study
Atrial Fibrillation
Primary: Percentage of Participants With Early Onset Primary Adverse Events — 2.6 Percentage of participants
N/A N=156 TactiSense IDE Trial of TactiCath SE for Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: Rate of Serious Adverse Events — 7 Participants — p=<0.0001
Phase 2 N=260 Surgical Ablation Versus No Surgical Ablation for Patients With Atrial Fibrillation Undergoing Mitral Valve Surgery
Atrial Fibrillation · Mitral Valve Insufficiency · Mitral Valve Stenosis
Primary: Freedom From Atrial Fibrillation — 31.1; 61.8 percentage of patients